Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine
Authors
Keywords
Vaccines, Vaccination and immunization, Typhoid, Conjugate vaccines, Booster doses, Adverse events, Fevers, Children
Journal
PLoS One
Volume 14, Issue 2, Pages e0211784
Publisher
Public Library of Science (PLoS)
Online
2019-02-14
DOI
10.1371/journal.pone.0211784
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children
- (2018) Maria Rosario Capeding et al. VACCINE
- Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15
- (2018) Brian Wahl et al. Lancet Global Health
- Combined effect of PCV10 and meningococcal C conjugate vaccination on meningitis mortality among children under five years of age in Brazil
- (2017) Ana Luiza Bierrenbach et al. Human Vaccines & Immunotherapeutics
- The Burden of Typhoid and Paratyphoid in India: Systematic Review and Meta-analysis
- (2016) Jacob John et al. PLoS Neglected Tropical Diseases
- Risk Factors of Typhoid Infection in the Indonesian Archipelago
- (2016) Sandra Alba et al. PLoS One
- Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study
- (2015) Vadrevu Krishna Mohan et al. CLINICAL INFECTIOUS DISEASES
- Environmental Transmission of Typhoid Fever in an Urban Slum
- (2015) Adam Akullian et al. PLoS Neglected Tropical Diseases
- Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials
- (2013) Zulfiqar A Bhutta et al. LANCET INFECTIOUS DISEASES
- Salmonella Infections
- (2013) J. C. Christenson PEDIATRICS IN REVIEW
- Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines
- (2013) M. Tontini et al. VACCINE
- Population-Based Incidence of Typhoid Fever in an Urban Informal Settlement and a Rural Area in Kenya: Implications for Typhoid Vaccine Use in Africa
- (2012) Robert F. Breiman et al. PLoS One
- Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010
- (2012) Geoffrey C. Buckle et al. Journal of Global Health
- The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant Vaccines
- (2011) Vu Dinh Thiem et al. Clinical and Vaccine Immunology
- Physical and Chemical Characterization and Immunologic Properties of Salmonella enterica Serovar Typhi Capsular Polysaccharide-Diphtheria Toxoid Conjugates
- (2009) C. Cui et al. Clinical and Vaccine Immunology
- Global Trends in Typhoid and Paratyphoid Fever
- (2009) John A. Crump et al. CLINICAL INFECTIOUS DISEASES
- a study of typhoid fever in five Asian countries: disease burden and implications for controls
- (2008) R Leon Ochiai BULLETIN OF THE WORLD HEALTH ORGANIZATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started